VYNE Therapeutics Inc.: VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis
Oral, once-daily doses of VYN202 being evaluated in subjects with moderate-to-severe plaque psoriasis Top-line data from the 12-week double-blind trial expected by year-end 2025 Phase 1b trial designe ...
ALFA, S.A.B. de C.V.: Alfa|SIGMA reports Comparable EBITDA of US $1 billion in 2024, with Alpek as Discontinued Operations
SAN PEDRO GARZA GARCÍA, N.L., Mexico, Feb. 18, 2025 /PRNewswire/ -- ALFA, S.A.B. de C.V. (BMV: ALFAA) ("ALFA") announced today its unaudited results for the fourth ...